Nektar Therapeutics (NKTR) COO John Nicholson Sells 5,982 Shares
Nektar Therapeutics (NASDAQ:NKTR) COO John Nicholson sold 5,982 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $38.25, for a total value of $228,811.50. Following the completion of the sale, the chief operating officer now owns 174,477 shares in the company, valued at $6,673,745.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Nektar Therapeutics stock traded down $0.22 on Monday, reaching $38.01. 2,486,195 shares of the company’s stock were exchanged, compared to its average volume of 3,133,722. The stock has a market capitalization of $6.62 billion, a price-to-earnings ratio of -69.11 and a beta of 2.91. Nektar Therapeutics has a 52 week low of $33.50 and a 52 week high of $111.36. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.80 and a current ratio of 13.93.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.07. The firm had revenue of $27.80 million for the quarter, compared to analysts’ expectations of $26.08 million. Nektar Therapeutics had a return on equity of 79.66% and a net margin of 59.71%. The company’s revenue for the quarter was down 81.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.37 EPS. On average, equities research analysts forecast that Nektar Therapeutics will post 3.66 EPS for the current year.
A number of research firms have issued reports on NKTR. ValuEngine cut Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday. TheStreet cut Nektar Therapeutics from a “c” rating to a “d+” rating in a report on Wednesday, November 7th. HC Wainwright set a $47.00 price target on Nektar Therapeutics and gave the stock a “hold” rating in a report on Monday, November 12th. Canaccord Genuity cut their price target on Nektar Therapeutics from $94.00 to $86.00 and set a “buy” rating on the stock in a report on Tuesday, November 13th. Finally, Cowen restated a “buy” rating and set a $86.00 price target on shares of Nektar Therapeutics in a report on Thursday, November 8th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Nektar Therapeutics currently has an average rating of “Hold” and an average target price of $85.78.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Featured Story: Stock Symbols and CUSIP Explained
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.